Induction of partial immune tolerance to factor VIII through prior mucosal exposure to the factor VIII C2 domain

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 10, 2006, Pages 2172-2179

  Rawle, F E ^a   Pratt, K P ^b   Labelle, A ^a   Weiner, H L ^c   Hough, C ^a   Lillicrap, D ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Factor VIII; Hemophilia; Immune tolerance; Inhibitors; Oral tolerance

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; CD4 ANTIGEN; INTERLEUKIN 10; NEUTRALIZING ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG PURIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOPHILIA A; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SPLEEN CELL;

ADMINISTRATION, INTRANASAL; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIII; FEMALE; HEMOPHILIA A; IMMUNE TOLERANCE; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MUCOUS MEMBRANE; PROTEIN STRUCTURE, TERTIARY; SPLEEN; TIME FACTORS;

EID: 33748745477     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02118.x     Document Type: Article

References (32)

1. Wright J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia 2003; 9: 418-35.
2. Dimichele D. Inhibitors: Resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 280-7.
3. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; ii: 933.
4. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors-twenty years' 'Bonn protocol'. Vox Sang 1996; 70: 30-5.
5. Kroner BL. Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 1999; 77: 33-7.
6. Tian J, Atkinson MA, Clare-Salzler M, Herschenfeld A, Forsthuber T, Lehmann PV, Kaufman DL. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 1996; 183: 1561-7.
7. Myers LK, Seyer JM, Stuart JM, Kang AH. Suppression of murine collagen-induced arthritis by nasal administration of collagen. Immunology 1997; 90: 161-4.
8. Im SH, Barchan D, Fuchs S, Souroujon MC. Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis. J Neuroimmunol 2000; 111: 161-8.
9. Weiner HL. Oral tolerance for the treatment of autoimmune diseases. Annu Rev Med 1997; 48: 341-51.
10. Van Houten N, Blake SF. Direct measurement of anergy of antigen-specific T cells following oral tolerance induction. J Immunol 1996; 157: 1337-41.
11. Chen Y, Inobe J, Marks R, Gonnella P, Kuchroo VK, Weiner HL. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995; 376: 177-80.
12. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 1994; 265: 1237-40.
13. Metzler B, Wraith DC. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: Influence of MHC binding affinity. Int Immunol 1993; 5: 1159-65.
14. Jansen IM, Fischer K, Van Der Bom JG, Van Den Berg HM. No protective effect of breastfeeding on inhibitor formation in severe hemophilia. Pediatr Hematol Oncol 2005; 22: 575-80.
15. Knobe KE, Tengborn LI, Petrini P, Ljung RC. Breastfeeding does not influence the development of inhibitors in haemophilia. Haemophilia 2002; 8: 657-9.
16. Terada K, Yagi Y, Niizuma T, Kataoka N. Is oral tolerance therapy possible for haemophilia with inhibitors? Vox Sang 2001; 80: 61-2.
17. Lindgren A, Wadenvik H, Tarkowski A, Tengborn L. Does peroral administration of factor VIII induce oral tolerance in patients with acquired haemophilia A? Thromb Haemost 2000; 83: 632-3.
18. Rawle FE, Shi CX, Brown B, McKinven A, Tinlin S, Graham FL, Hough C, Lillicrap D. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains. J Gene Med 2004; 6: 1358-68.
19. Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999; 402: 439-42.
20. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, Fratantoni J, Green D, Hampton J, Hilgartner M, Levine P, Lazerson J, McMillan C, Penner J, Shapiro S, Shulman NR. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
21. Ling M, Duncan EM, Rodgers SE, Street AM, Lloyd JV. Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay. J Thromb Haemost 2003; 1: 2548-53.
22. Pratt KP, Qian J, Ellaban E, Okita DK, Diethelm-Okita BM, Conti-Fine B, Scott DW. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site. Thromb Haemost 2004; 92: 522-8.
23. Reding MT, Wu H, Krampf M, Okita DK, Diethelm-Okita BM, Christie BA, Key NS, Conti-Fine BM. Sensitization of CD4+ T cells to coagulation factor VIII: Response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 2000; 84: 643-52.
24. Lollar P. Characterization of factor VIII B-cell inhibitory epitopes. Thromb Haemost 1999; 82: 505-8.
25. Reding MT, Okita DK, Diethelm-Okita BM, Anderson TA, Conti-Fine BM. Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII. J Thromb Haemost 2003; 1: 1777-84.
26. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol Rev 2001; 182: 68-79.
27. Jiang H, Chess L. An integrated model of immunoregulation mediated by regulatory T cell subsets. Adv Immunol 2004; 83: 253-88.
28. Zhang X, Izikson L, Liu L, Weiner HL. Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. J Immunol 2001; 167: 4245-53.
29. Kraus TA, Brimnes J, Muong C, Liu JH, Moran TM, Tappenden KA, Boros P, Mayer L. Induction of mucosal tolerance in Peyer's patch-deficient, ligated small bowel loops. J Clin Invest 2005; 115: 2234-43.
30. Lei TC, Scott DW. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood 2005; 105: 4865-70.
31. Alpan O, Kamala T, Velander W, Knight J, OSickey T, High K, Matzinger P. An inexpensive and easy method of inducing tolerance to human FIX. Blood 2001; 98: 3430 (abstract).
32. Rawle F, Labelle A, Davie E, Pratt K, Lillicrap D. Prevention of anti-FVIII inhibitor formation post-protein infusion in hemophilic mice by prior feeding of the FVIII-C2 domain. Blood 2004; 104: 39 (abstract).